A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens

British Journal of Cancer

Volumn 95, Issue 12, 2006, Pages 1637-1641

  Jeung, H C ^a,b   Rha, S Y ^a,b,c   Cho, B C ^b,c   Yoo, N C ^b,c   Roh, J K ^a,b,c   Roh, W J ^a   Chung, H C ^a,b,c   Ahn, J B ^b,c  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

Colorectal adenocarcinoma; Irinotecan resistant; Oxaliplatin resistant; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CAPECITABINE; CISPLATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DRUG DOSE REDUCTION; DYSPEPSIA; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEMATOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER FUNCTION; MALE; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; REPEATED DRUG DOSE; SALVAGE THERAPY; SIDE EFFECT; SKIN PIGMENTATION; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG COMBINATIONS; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; SALVAGE THERAPY; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME;

EID: 33845666953     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603468     Document Type: Article

References (21)

1. Alberts SR, Sinicrope FA, Grothey A (2005) N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer. Clin Colorectal Cancer 5: 211-213
2. Cao S, Baccanari DP, Rustum YM, Davis ST, Tansik RL, Porter DJT, Spector T (2000) alpha-fluoro-beta-alanine: effects on the antitumor activity and toxicity of 5-fluorouracil. Biochem Pharmacol 59: 953-960
3. Chong G, Dickson JLB, Cunningham D, Norman AR, Rao S, Hill ME, Price TJ, Oates J, Tebbutt N (2005) Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 93: 510-514
4. Chu QS, Hammond LA, Schwarz G, Ochoa L, Rha SY, Denis L, Molpus K, Roedig B, Letrent SP, Damle B, DeCillis AP, Rowinsky EK (2004) Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28- day schedule on patients with advanced malignancies. Clin Cancer Res 10: 4913-4921
5. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 351: 337-345
6. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer C, Papamichael D, Le Bali N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947
7. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355: 1041-1047
8. Glimelius B, Hoffman K, Graf W, Pahlman L, Sjoden PO (1994) Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer: The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Cancer 73: 556-562
9. Gubanski M, Naucler G, Almerud A, Lidestahl A, Lind PARM (2005) Capecitabine as third line therapy in patients with advanced colorectal cancer. Acta Oncologica 44: 236-239
10. Hoff PM, Pazdur R, Lassere Y, Carter S, Samid D, Polito D, Abbruzzese JL (2004) Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol 22: 2078-2083
11. Kim NK, Park JK, Lee KY, Yun SH, Sohn SK, Min JS (2002) Prognostic factors influencing the recurrence pattern and survival rates in curatively resected colorectal cancer. J Korean Surg Soc 62: 421-429
12. Matin K, Jacobs SA, Richards T, Wong MK, Earle M, Evans T, Troetschel M, Ferri W, Friedland D, Pinkerton R, Volkin R, Wieand S, Ramathan RK (2005) A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer. Am J Clin Oncol 28: 439-444
13. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, Taguchi T (2000) Phase II study of S-1, a novel fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer 83: 141-145
14. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343: 905-914
15. Saltz LB, Meropol NJ, Loehrer Sr PJ, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201-1208
16. Shirao K, Ohtsu A, Takada H, Mitachi Y, Hirakawa K, Horikoshi N, Okamura T, Hirata K, Saitoh S, Isomoto H, Satoh A (2004) Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 100: 2355-2361
17. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M (1996) Antitumor activity of 1M tegafur-0.4M 5-chloro-2,4-dihydropyridine-1M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56: 2602-2606
18. Simon R (1989) Optimal two-stage design for phase II clinical trials. Controlled Clin Trials 10: 1-10
19. Tsukioka Y, Matsumura Y, Hamaguchi T, Goto M, Muro K, Yamada Y, Shirao K (2001) Complete response achieved following administration of S-1 in a patient with adrenal gland metastasis of 5-FU-resistant gastric cancer: a case report. Jpn J Clin Oncol 31: 450-453
20. Tyagi P (2005) Adjuvant irinotecan regimens in combination with infusional 5-fluorouracil/leucovorin fail to improve outcomes in surgically resected colorectal cancer. Clin Colorectal Cancer 5: 86-88
21. Van den Brande J, Schoffski P, Schellens JHM, Roth AD, Duffaud F, Weigang-Kohler K, Reinke F, Wanders J, de Boer RF, Vermorken JB, Fumoleau P (2003) EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 88: 648-653